1 1166 109 CONTRIBUTION OF DNMT1 TO NEUROPATHIC PAIN GENESIS PARTIALLY THROUGH EPIGENETICALLY REPRESSING KCNA2 IN PRIMARY AFFERENT NEURONS. EXPRESSIONAL CHANGES OF PAIN-ASSOCIATED GENES IN PRIMARY SENSORY NEURONS OF DRG ARE CRITICAL FOR NEUROPATHIC PAIN GENESIS. DNA METHYLTRANSFERASE (DNMT)-TRIGGERED DNA METHYLATION SILENCES GENE EXPRESSION. WE SHOW HERE THAT DNMT1, A CANONICAL MAINTENANCE METHYLTRANSFERASE, ACTS AS THE DE NOVO DNMT AND IS REQUIRED FOR NEUROPATHIC PAIN GENESIS LIKELY THROUGH REPRESSING AT LEAST DRG KCNA2 GENE EXPRESSION IN MALE MICE. PERIPHERAL NERVE INJURY UPREGULATED DNMT1 EXPRESSION IN THE INJURED DRG THROUGH THE TRANSCRIPTION FACTOR CAMP RESPONSE ELEMENT BINDING PROTEIN-TRIGGERED TRANSCRIPTIONAL ACTIVATION OF DNMT1 GENE. BLOCKING THIS UPREGULATION PREVENTED NERVE INJURY-INDUCED DNA METHYLATION WITHIN THE PROMOTER AND 5'-UNTRANSLATED REGION OF KCNA2 GENE, RESCUED KCNA2 EXPRESSION AND TOTAL KV CURRENT, ATTENUATED HYPEREXCITABILITY IN THE INJURED DRG NEURONS, AND ALLEVIATED NERVE INJURY-INDUCED PAIN HYPERSENSITIVITIES. GIVEN THAT KCNA2 IS A KEY PLAYER IN NEUROPATHIC PAIN, OUR FINDINGS SUGGEST THAT DRG DNMT1 MAY BE A POTENTIAL TARGET FOR NEUROPATHIC PAIN MANAGEMENT.SIGNIFICANCE STATEMENT IN THE PRESENT STUDY, WE REPORTED THAT DNMT1, A CANONICAL DNA MAINTENANCE METHYLTRANSFERASE, IS UPREGULATED VIA THE ACTIVATION OF THE TRANSCRIPTION FACTOR CREB IN THE INJURED DRG AFTER PERIPHERAL NERVE INJURY. THIS UPREGULATION WAS RESPONSIBLE FOR NERVE INJURY-INDUCED DE NOVO DNA METHYLATION WITHIN THE PROMOTER AND 5'-UNTRANSLATED REGION OF THE KCNA2 GENE, REDUCTIONS IN KCNA2 EXPRESSION AND KV CURRENT AND INCREASES IN NEURONAL EXCITABILITY IN THE INJURED DRG. SINCE PHARMACOLOGICAL INHIBITION OR GENETIC KNOCKDOWN OF DRG DNMT1 ALLEVIATED NERVE INJURY-INDUCED PAIN HYPERSENSITIVITIES, DRG DNMT1 CONTRIBUTES TO NEUROPATHIC PAIN GENESIS PARTIALLY THROUGH REPRESSION OF DRG KCNA2 GENE EXPRESSION. 2019 2 2885 43 G9A PARTICIPATES IN NERVE INJURY-INDUCED KCNA2 DOWNREGULATION IN PRIMARY SENSORY NEURONS. NERVE INJURY-INDUCED DOWNREGULATION OF VOLTAGE-GATED POTASSIUM CHANNEL SUBUNIT KCNA2 IN THE DORSAL ROOT GANGLION (DRG) IS CRITICAL FOR DRG NEURONAL EXCITABILITY AND NEUROPATHIC PAIN GENESIS. HOWEVER, HOW NERVE INJURY CAUSES THIS DOWNREGULATION IS STILL ELUSIVE. EUCHROMATIC HISTONE-LYSINE N-METHYLTRANSFERASE 2, ALSO KNOWN AS G9A, METHYLATES HISTONE H3 ON LYSINE RESIDUE 9 TO PREDOMINANTLY PRODUCE A DYNAMIC HISTONE DIMETHYLATION, RESULTING IN CONDENSED CHROMATIN AND GENE TRANSCRIPTIONAL REPRESSION. WE SHOWED HERE THAT BLOCKING NERVE INJURY-INDUCED INCREASE IN G9A RESCUED KCNA2 MRNA AND PROTEIN EXPRESSION IN THE AXOTOMIZED DRG AND ATTENUATED THE DEVELOPMENT OF NERVE INJURY-INDUCED PAIN HYPERSENSITIVITY. MIMICKING THIS INCREASE DECREASED KCNA2 MRNA AND PROTEIN EXPRESSION, REDUCED KV CURRENT, AND INCREASED EXCITABILITY IN THE DRG NEURONS AND LED TO SPINAL CORD CENTRAL SENSITIZATION AND NEUROPATHIC PAIN-LIKE SYMPTOMS. G9A MRNA IS CO-LOCALIZED WITH KCNA2 MRNA IN THE DRG NEURONS. THESE FINDINGS INDICATE THAT G9A CONTRIBUTES TO NEUROPATHIC PAIN DEVELOPMENT THROUGH EPIGENETIC SILENCING OF KCNA2 IN THE AXOTOMIZED DRG. 2016 3 6424 45 THE TRANSCRIPTION FACTOR C/EBPBETA IN THE DORSAL ROOT GANGLION CONTRIBUTES TO PERIPHERAL NERVE TRAUMA-INDUCED NOCICEPTIVE HYPERSENSITIVITY. CHANGES IN GENE TRANSCRIPTION IN THE DORSAL ROOT GANGLION (DRG) AFTER NERVE TRAUMA CONTRIBUTE TO THE GENESIS OF NEUROPATHIC PAIN. WE REPORT THAT PERIPHERAL NERVE TRAUMA CAUSED BY CHRONIC CONSTRICTION INJURY (CCI) INCREASED THE ABUNDANCE OF THE TRANSCRIPTION FACTOR C/EBPBETA (CCAAT/ENHANCER BINDING PROTEIN BETA) IN THE DRG. BLOCKING THIS INCREASE MITIGATED THE DEVELOPMENT AND MAINTENANCE OF CCI-INDUCED MECHANICAL, THERMAL, AND COLD PAIN HYPERSENSITIVITIES WITHOUT AFFECTING BASAL RESPONSES TO ACUTE PAIN AND LOCOMOTOR ACTIVITY. CONVERSELY, MIMICKING THIS INCREASE PRODUCED HYPERSENSITIVITY TO MECHANICAL, THERMAL, OR COLD PAIN. IN THE IPSILATERAL DRG, C/EBPBETA PROMOTED A DECREASE IN THE ABUNDANCE OF THE VOLTAGE-GATED POTASSIUM CHANNEL SUBUNIT KV1.2 AND MU OPIOID RECEPTOR (MOR) AT THE MRNA AND PROTEIN LEVELS, WHICH WOULD BE PREDICTED TO INCREASE EXCITABILITY IN THE IPSILATERAL DRG NEURONS AND REDUCE THE EFFICACY OF MORPHINE ANALGESIA. THESE EFFECTS REQUIRED C/EPBBETA-MEDIATED TRANSCRIPTIONAL ACTIVATION OF EHMT2 (EUCHROMATIC HISTONE-LYSINE N-METHYLTRANSFERASE 2), WHICH ENCODES G9A, AN EPIGENETIC SILENCER OF THE GENES ENCODING KV1.2 AND MOR. BLOCKING THE INCREASE IN C/EBPBETA IN THE DRG IMPROVED MORPHINE ANALGESIA AFTER CCI. THESE RESULTS SUGGEST THAT C/EBPBETA IS AN ENDOGENOUS INITIATOR OF NEUROPATHIC PAIN AND COULD BE A POTENTIAL TARGET FOR THE PREVENTION AND TREATMENT OF THIS DISORDER. 2017 4 5574 45 ROLE OF MICRORNA-143 IN NERVE INJURY-INDUCED UPREGULATION OF DNMT3A EXPRESSION IN PRIMARY SENSORY NEURONS. PERIPHERAL NERVE INJURY INCREASED THE EXPRESSION OF THE DNA METHYLTRANSFERASE 3A (DNMT3A) MRNA AND ITS ENCODING DNMT3A PROTEIN IN INJURED DORSAL ROOT GANGLIA (DRG). THIS INCREASE IS CONSIDERED AS AN ENDOGENOUS INSTIGATOR IN NEUROPATHIC PAIN GENESIS THROUGH EPIGENETIC SILENCING OF PAIN-ASSOCIATED GENES (SUCH AS OPRM1) IN INJURED DRG. HOWEVER, HOW DRG DNMT3A IS INCREASED FOLLOWING PERIPHERAL NERVE INJURY IS STILL ELUSIVE. WE REPORTED HERE THAT PERIPHERAL NERVE INJURY CAUSED BY THE FIFTH SPINAL NERVE LIGATION (SNL) DOWNREGULATED MICRORNA (MIR)-143 EXPRESSION IN INJURED DRG. THIS DOWNREGULATION WAS REQUIRED FOR SNL-INDUCED DRG DNMT3A INCREASE AS RESCUING MIR-143 DOWNREGULATION THROUGH MICROINJECTION OF MIR-143 MIMICS INTO INJURED DRG BLOCKED THE SNL-INDUCED INCREASE IN DNMT3A AND RESTORED THE SNL-INDUCED DECREASES IN OPRM1 MRNA AND ITS ENCODING MU OPIOID RECEPTOR (MOR) IN INJURED DRG, IMPAIRED SPINAL CORD CENTRAL SENSITIZATION AND NEUROPATHIC PAIN, AND IMPROVED MORPHINE ANALGESIC EFFECTS FOLLOWING SNL. MIMICKING SNL-INDUCED DRG MIR-143 DOWNREGULATION THROUGH DRG MICROINJECTION OF MIR143 INHIBITORS IN NAIVE RATS INCREASED THE EXPRESSION OF DNMT3A AND REDUCED THE EXPRESSION OF OPRM1 MRNA AND MOR IN INJECTED DRG AND PRODUCED NEUROPATHIC PAIN-LIKE SYMPTOMS. THESE FINDINGS SUGGEST THAT MIR-143 IS A NEGATIVE REGULATOR IN DNMT3A EXPRESSION IN THE DRG UNDER NEUROPATHIC PAIN CONDITIONS AND MAY BE A POTENTIAL TARGET FOR THERAPEUTIC MANAGEMENT OF NEUROPATHIC PAIN. 2017 5 4098 54 MBD1 CONTRIBUTES TO THE GENESIS OF ACUTE PAIN AND NEUROPATHIC PAIN BY EPIGENETIC SILENCING OF OPRM1 AND KCNA2 GENES IN PRIMARY SENSORY NEURONS. THE TRANSMISSION OF NORMAL SENSORY AND/OR ACUTE NOXIOUS INFORMATION REQUIRES INTACT EXPRESSION OF PAIN-ASSOCIATED GENES WITHIN THE PAIN PATHWAYS OF NERVOUS SYSTEM. EXPRESSIONAL CHANGES OF THESE GENES AFTER PERIPHERAL NERVE INJURY ARE ALSO CRITICAL FOR NEUROPATHIC PAIN INDUCTION AND MAINTENANCE. METHYL-CPG-BINDING DOMAIN PROTEIN 1 (MBD1), AN EPIGENETIC REPRESSOR, REGULATES GENE TRANSCRIPTIONAL ACTIVITY. WE REPORT HERE THAT MBD1 IN THE PRIMARY SENSORY NEURONS OF DRG IS CRITICAL FOR THE GENESIS OF ACUTE PAIN AND NEUROPATHIC PAIN AS DRG MBD1-DEFICIENT MICE EXHIBIT THE REDUCED RESPONSES TO ACUTE MECHANICAL, HEAT, COLD, AND CAPSAICIN STIMULI AND THE BLUNTED NERVE INJURY-INDUCED PAIN HYPERSENSITIVITIES. FURTHERMORE, DRG OVEREXPRESSION OF MBD1 LEADS TO SPONTANEOUS PAIN AND EVOKED PAIN HYPERSENSITIVITIES IN THE WT MICE AND RESTORES ACUTE PAIN SENSITIVITIES IN THE MBD1-DEFICIENT MICE. MECHANISTICALLY, MDB1 REPRESSES OPRM1 AND KCNA2 GENE EXPRESSION BY RECRUITING DNA METHYLTRANSFERASE DNMT3A INTO THESE TWO GENE PROMOTERS IN THE DRG NEURONS. DRG MBD1 IS LIKELY A KEY PLAYER UNDER THE CONDITIONS OF ACUTE PAIN AND NEUROPATHIC PAIN.SIGNIFICANCE STATEMENT IN THE PRESENT STUDY, WE REVEALED THAT THE MICE WITH DEFICIENCY OF METHYL-CPG-BINDING DOMAIN PROTEIN 1 (MBD1), AN EPIGENETIC REPRESSOR, IN THE DRG DISPLAYED THE REDUCED RESPONSES TO ACUTE NOXIOUS STIMULI AND THE BLUNTED NEUROPATHIC PAIN. WE ALSO SHOWED THAT DRG OVEREXPRESSION OF MBD1 PRODUCED THE HYPERSENSITIVITIES TO NOXIOUS STIMULI IN THE WT MICE AND RESCUED ACUTE PAIN SENSITIVITIES IN THE MBD1-DEFICIENT MICE. WE HAVE ALSO PROVIDED THE EVIDENCE THAT MDB1 REPRESSES OPRM1 AND KCNA2 GENE EXPRESSION BY RECRUITING DNA METHYLTRANSFERASE DNMT3A INTO THESE TWO GENE PROMOTERS IN THE DRG NEURONS. DRG MBD1 MAY PARTICIPATE IN THE GENESIS OF ACUTE PAIN AND NEUROPATHIC PAIN LIKELY THROUGH REGULATING DNMT3A-CONTROLLED OPRM1 AND KCNA2 GENE EXPRESSION IN THE DRG NEURONS. 2018 6 2310 32 EPIGENETIC REGULATION OF CHRONIC PAIN. CHRONIC PAIN ARISING FROM PERIPHERAL INFLAMMATION AND TISSUE OR NERVE INJURY IS A COMMON CLINICAL SYMPTOM. ALTHOUGH INTENSIVE RESEARCH ON THE NEUROBIOLOGICAL MECHANISMS OF CHRONIC PAIN HAS BEEN CARRIED OUT DURING PREVIOUS DECADES, THIS DISORDER IS STILL POORLY MANAGED BY CURRENT DRUGS SUCH AS OPIOIDS AND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS. INFLAMMATION, TISSUE INJURY AND/OR NERVE INJURY-INDUCED CHANGES IN GENE EXPRESSION IN SENSORY NEURONS OF THE DORSAL ROOT GANGLION, SPINAL CORD DORSAL HORN AND PAIN-ASSOCIATED BRAIN REGIONS ARE THOUGHT TO PARTICIPATE IN CHRONIC PAIN GENESIS; HOWEVER, HOW THESE CHANGES OCCUR IS STILL ELUSIVE. EPIGENETIC MODIFICATIONS INCLUDING DNA METHYLATION AND COVALENT HISTONE MODIFICATIONS CONTROL GENE EXPRESSION. RECENT STUDIES HAVE SHOWN THAT PERIPHERAL NOXIOUS STIMULATION CHANGES DNA METHYLATION AND HISTONE MODIFICATIONS AND THAT THESE CHANGES MAY BE RELATED TO THE INDUCTION OF PAIN HYPERSENSITIVITY UNDER CHRONIC PAIN CONDITIONS. THIS REVIEW SUMMARIZES THE CURRENT KNOWLEDGE AND PROGRESS IN EPIGENETIC RESEARCH IN CHRONIC PAIN AND DISCUSSES THE POTENTIAL ROLE OF EPIGENETIC MODIFICATIONS AS THERAPEUTIC ANTINOCICEPTIVE TARGETS IN THIS DISORDER. 2015 7 1654 46 DORSAL ROOT GANGLIA COACTIVATOR-ASSOCIATED ARGININE METHYLTRANSFERASE 1 CONTRIBUTES TO PERIPHERAL NERVE INJURY-INDUCED PAIN HYPERSENSITIVITIES. NEUROPATHIC PAIN IS ASSOCIATED WITH GENE EXPRESSION CHANGES WITHIN THE DORSAL ROOT GANGLION (DRG) AFTER PERIPHERAL NERVE INJURY, WHICH INVOLVES EPIGENETIC MECHANISMS. COACTIVATOR-ASSOCIATED ARGININE METHYLTRANSFERASE 1 (CARM1), AN EPIGENETIC ACTIVATOR, REGULATES GENE TRANSCRIPTIONAL ACTIVITY BY PROTEIN POSTTRANSLATIONAL MODIFICATIONS. HOWEVER, WHETHER CARM1 PLAYS AN ESSENTIAL ROLE IN THE DEVELOPMENT AND MAINTENANCE OF NEUROPATHIC PAIN IS UNKNOWN. WE REPORT HERE THAT PERIPHERAL NERVE INJURY INDUCED THE UPREGULATION OF THE MRNA AND PROTEIN EXPRESSION OF CARM1 IN THE INJURED DRG, AND BLOCKING ITS EXPRESSION THROUGH SMALL INTERFERING RNA (SIRNA) IN THE INJURED DRG ATTENUATED THE DEVELOPMENT AND MAINTENANCE OF NEUROPATHIC PAIN. FURTHERMORE, PHARMACOLOGICAL INHIBITION OF CARM1 MITIGATED PERIPHERAL NERVE INJURY-INDUCED MECHANICAL ALLODYNIA AND THERMAL HYPERALGESIA. GIVEN THAT CARM1 INHIBITION OR KNOCKDOWN ATTENUATED THE INDUCTION AND MAINTENANCE OF NEUROPATHIC PAIN AFTER PERIPHERAL NERVE INJURY, OUR FINDINGS SUGGEST THAT CARM1 MAY SERVE AS A PROMISING THERAPEUTIC TARGET FOR NEUROPATHIC PAIN TREATMENT IN CLINICAL APPLICATIONS. 2018 8 4713 35 NON-CODING RNA AND N6-METHYLADENOSINE MODIFICATION PLAY CRUCIAL ROLES IN NEUROPATHIC PAIN. AFTER PERIPHERAL NERVE INJURY, PAIN SIGNALS ARE TRANSMITTED FROM PRIMARY SENSORY NEURONS IN THE DORSAL ROOT GANGLION (DRG) TO THE CENTRAL NERVOUS SYSTEM. EPIGENETIC MODIFICATION AFFECTS NEUROPATHIC PAIN THROUGH ALTERATIONS IN THE GENE EXPRESSION IN PAIN-RELATED AREAS AND GLIAL CELL ACTIVATION. RECENT STUDIES HAVE SHOWN THAT NON-CODING RNA AND N6-METHYLADENOSINE (M6A) METHYLATION MODIFICATION PLAY PIVOTAL REGULATORY ROLES IN THE OCCURRENCE AND MAINTENANCE OF NEUROPATHIC PAIN. DYSREGULATION OF THE RNA M6A LEVEL VIA DYNAMIC CHANGES IN METHYLTRANSFERASE AND DEMETHYLASE AFTER CENTRAL OR PERIPHERAL NERVE INJURY COMMONLY REGULATES PAIN-ASSOCIATED GENES, CONTRIBUTING TO THE INDUCTION AND MAINTENANCE OF NEUROPATHIC PAIN. THE DYNAMIC PROCESS HAS SIGNIFICANT IMPLICATIONS FOR THE DEVELOPMENT AND MAINTENANCE OF NEUROPATHIC PAIN. HOWEVER, THE UNDERLYING MECHANISMS BY WHICH NON-CODING RNA AND M6A RNA MODIFICATION REGULATE NEUROPATHIC PAIN ARE NOT WELL-CHARACTERIZED. THIS ARTICLE ELUCIDATES THE MULTIPLE MECHANISMS OF NON-CODING RNA AND M6A METHYLATION IN THE CONTEXT OF NEUROPATHIC PAIN, AND SUMMARIZES ITS POTENTIAL FUNCTIONS AS WELL AS RECENT ADVANCES. 2022 9 4618 54 NERVE INJURY-INDUCED EPIGENETIC SILENCING OF OPIOID RECEPTORS CONTROLLED BY DNMT3A IN PRIMARY AFFERENT NEURONS. OPIOIDS ARE THE GOLD STANDARD FOR PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN, BUT THEIR ANALGESIC EFFECTS ARE UNSATISFACTORY IN PART DUE TO NERVE INJURY-INDUCED DOWNREGULATION OF OPIOID RECEPTORS IN DORSAL ROOT GANGLIA (DRG) NEURONS. HOW NERVE INJURY DRIVES SUCH DOWNREGULATION REMAINS ELUSIVE. DNA METHYLTRANSFERASE (DNMT)-TRIGGERED DNA METHYLATION REPRESSES GENE EXPRESSION. WE SHOW HERE THAT BLOCKING THE NERVE INJURY-INDUCED INCREASE IN DRG DNMT3A (A DE NOVO DNMT) RESCUED THE EXPRESSION OF OPRM1 AND OPRK1 MRNAS AND THEIR RESPECTIVE ENCODING MU-OPIOID RECEPTOR (MOR) AND KAPPA-OPIOID RECEPTOR (KOR) PROTEINS IN THE INJURED DRG. BLOCKING THIS INCREASE ALSO PREVENTED THE NERVE INJURY-INDUCED INCREASE IN DNA METHYLATION IN THE PROMOTER AND 5'-UNTRANSLATED REGION OF THE OPRM1 GENE IN THE INJURED DRG, RESTORED MORPHINE OR LOPERAMIDE (A PERIPHERAL ACTING MOR PREFERRING AGONIST) ANALGESIC EFFECTS, AND ATTENUATED THE DEVELOPMENT OF THEIR ANALGESIC TOLERANCE UNDER NEUROPATHIC PAIN CONDITIONS. MIMICKING THIS INCREASE REDUCED THE EXPRESSION OF OPRM1 AND OPRK1 MRNAS AND THEIR CODING MOR AND KOR IN DRG AND AUGMENTED MOR-GATED NEUROTRANSMITTER RELEASE FROM THE PRIMARY AFFERENTS. MECHANISTICALLY, DNMT3A REGULATION OF OPRM1 GENE EXPRESSION REQUIRED THE METHYL-CPG-BINDING PROTEIN 1, MBD1, AS MBD1 KNOCKOUT RESULTED IN THE DECREASED BINDING OF DNMT3A TO THE OPRM1 GENE PROMOTER AND BLOCKED THE DNMT3A-TRIGGERED REPRESSION OF OPRM1 GENE EXPRESSION IN DRG NEURONS. THESE DATA SUGGEST THAT DNMT3A IS REQUIRED FOR NERVE INJURY-INDUCED AND MBD1-MEDIATED EPIGENETIC SILENCING OF THE MOR AND KOR IN THE INJURED DRG. DNMT3A INHIBITION MAY SERVE AS A PROMISING ADJUVANT THERAPY FOR OPIOID USE IN NEUROPATHIC PAIN MANAGEMENT. 2017 10 4615 50 NERVE INJURY DIMINISHES OPIOID ANALGESIA THROUGH LYSINE METHYLTRANSFERASE-MEDIATED TRANSCRIPTIONAL REPRESSION OF MU-OPIOID RECEPTORS IN PRIMARY SENSORY NEURONS. THE MU-OPIOID RECEPTOR (MOR, ENCODED BY OPRM1) AGONISTS ARE THE MAINSTAY ANALGESICS FOR TREATING MODERATE TO SEVERE PAIN. NERVE INJURY CAUSES DOWN-REGULATION OF MORS IN THE DORSAL ROOT GANGLION (DRG) AND DIMINISHES THE OPIOID EFFECT ON NEUROPATHIC PAIN. HOWEVER, THE EPIGENETIC MECHANISMS UNDERLYING THE DIMINISHED MOR EXPRESSION CAUSED BY NERVE INJURY ARE NOT CLEAR. G9A (ENCODED BY EHMT2), A HISTONE 3 AT LYSINE 9 METHYLTRANSFERASE, IS A KEY CHROMATIN REGULATOR RESPONSIBLE FOR GENE SILENCING. IN THIS STUDY, WE DETERMINED THE ROLE OF G9A IN DIMINISHED MOR EXPRESSION AND OPIOID ANALGESIC EFFECTS IN ANIMAL MODELS OF NEUROPATHIC PAIN. WE FOUND THAT NERVE INJURY IN RATS INDUCED A LONG-LASTING REDUCTION IN THE EXPRESSION LEVEL OF MORS IN THE DRG BUT NOT IN THE SPINAL CORD. NERVE INJURY CONSISTENTLY INCREASED THE ENRICHMENT OF THE G9A PRODUCT HISTONE 3 AT LYSINE 9 DIMETHYLATION IN THE PROMOTER OF OPRM1 IN THE DRG. G9A INHIBITION OR SIRNA KNOCKDOWN FULLY REVERSED MOR EXPRESSION IN THE INJURED DRG AND POTENTIATED THE MORPHINE EFFECT ON PAIN HYPERSENSITIVITY INDUCED BY NERVE INJURY. IN MICE LACKING EHMT2 IN DRG NEURONS, NERVE INJURY FAILED TO REDUCE THE EXPRESSION LEVEL OF MORS AND THE MORPHINE EFFECT. IN ADDITION, G9A INHIBITION OR EHMT2 KNOCKOUT IN DRG NEURONS NORMALIZED NERVE INJURY-INDUCED REDUCTION IN THE INHIBITORY EFFECT OF THE OPIOID ON SYNAPTIC GLUTAMATE RELEASE FROM PRIMARY AFFERENT NERVES. OUR FINDINGS INDICATE THAT G9A CONTRIBUTES CRITICALLY TO TRANSCRIPTIONAL REPRESSION OF MORS IN PRIMARY SENSORY NEURONS IN NEUROPATHIC PAIN. G9A INHIBITORS MAY BE USED TO ENHANCE THE OPIOID ANALGESIC EFFECT IN THE TREATMENT OF CHRONIC NEUROPATHIC PAIN. 2016 11 4617 45 NERVE INJURY-INDUCED CHRONIC PAIN IS ASSOCIATED WITH PERSISTENT DNA METHYLATION REPROGRAMMING IN DORSAL ROOT GANGLION. NERVE INJURY-INDUCED HYPERACTIVITY OF PRIMARY SENSORY NEURONS IN THE DORSAL ROOT GANGLION (DRG) CONTRIBUTES TO CHRONIC PAIN DEVELOPMENT, BUT THE UNDERLYING EPIGENETIC MECHANISMS REMAIN POORLY UNDERSTOOD. HERE WE DETERMINED GENOME-WIDE CHANGES IN DNA METHYLATION IN THE NERVOUS SYSTEM IN NEUROPATHIC PAIN. SPINAL NERVE LIGATION (SNL), BUT NOT PACLITAXEL TREATMENT, IN MALE SPRAGUE DAWLEY RATS INDUCED A CONSISTENT LOW-LEVEL HYPOMETHYLATION IN THE CPG SITES IN THE DRG DURING THE ACUTE AND CHRONIC PHASES OF NEUROPATHIC PAIN. DNA METHYLATION REMODELING IN THE DRG OCCURRED EARLY AFTER SNL AND PERSISTED FOR AT LEAST 3 WEEKS. SNL CAUSED DNA METHYLATION CHANGES AT 8% OF CPG SITES WITH PREVAILING HYPOMETHYLATION OUTSIDE OF CPG ISLANDS, IN INTRONS, INTERGENIC REGIONS, AND REPETITIVE SEQUENCES. IN CONTRAST, SNL CAUSED MORE GAINS OF METHYLATION IN THE SPINAL CORD AND PREFRONTAL CORTEX. THE DNA METHYLATION CHANGES IN THE INJURED DRGS RECAPITULATED DEVELOPMENTAL REPROGRAMMING AT THE NEONATAL STAGE. METHYLATION REPROGRAMMING WAS CORRELATED WITH INCREASED GENE EXPRESSION VARIABILITY. A DIET DEFICIENT IN METHYL DONORS INDUCED HYPOMETHYLATION AND PAIN HYPERSENSITIVITY. INTRATHECAL ADMINISTRATION OF THE DNA METHYLTRANSFERASE INHIBITOR RG108 CAUSED LONG-LASTING PAIN HYPERSENSITIVITY. DNA METHYLATION REPROGRAMMING IN THE DRG THUS CONTRIBUTES TO NERVE INJURY-INDUCED CHRONIC PAIN. RESTORING DNA METHYLATION MAY REPRESENT A NEW THERAPEUTIC APPROACH TO TREAT NEUROPATHIC PAIN.SIGNIFICANCE STATEMENT EPIGENETIC MECHANISMS ARE CRITICALLY INVOLVED IN THE TRANSITION FROM ACUTE TO CHRONIC PAIN AFTER NERVE INJURY. HOWEVER, GENOME-WIDE CHANGES IN DNA METHYLATION IN THE NERVOUS SYSTEM AND THEIR ROLES IN NEUROPATHIC PAIN DEVELOPMENT REMAIN UNCLEAR. HERE WE USED DIGITAL RESTRICTION ENZYME ANALYSIS OF METHYLATION TO QUANTITATIVELY DETERMINE GENOME-WIDE DNA METHYLATION CHANGES CAUSED BY NERVE INJURY. WE SHOWED THAT NERVE INJURY CAUSED DNA METHYLATION CHANGES AT 8% OF CPG SITES WITH PREVAILING HYPOMETHYLATION OUTSIDE OF CPG ISLANDS IN THE DORSAL ROOT GANGLION. REDUCING DNA METHYLATION INDUCED PAIN HYPERSENSITIVITY, WHEREAS INCREASING DNA METHYLATION ATTENUATED NEUROPATHIC PAIN. THESE FINDINGS EXTEND OUR UNDERSTANDING OF THE EPIGENETIC MECHANISM OF CHRONIC NEUROPATHIC PAIN AND SUGGEST NEW STRATEGIES TO TREAT NERVE INJURY-INDUCED CHRONIC PAIN. 2018 12 2179 34 EPIGENETIC MECHANISMS OF NEURAL PLASTICITY IN CHRONIC NEUROPATHIC PAIN. NEUROPATHIC PAIN IS A CHALLENGING CLINICAL PROBLEM AND REMAINS DIFFICULT TO TREAT. ALTERED GENE EXPRESSION IN PERIPHERAL SENSORY NERVES AND NEURONS DUE TO NERVE INJURY IS WELL DOCUMENTED AND CONTRIBUTES CRITICALLY TO THE SYNAPTIC PLASTICITY IN THE SPINAL CORD AND THE INITIATION AND MAINTENANCE OF CHRONIC PAIN. HOWEVER, OUR UNDERSTANDING OF THE EPIGENETIC MECHANISMS REGULATING THE TRANSCRIPTION OF PRO-NOCICEPTIVE (E.G., NMDA RECEPTORS AND ALPHA2DELTA-1) AND ANTINOCICEPTIVE (E.G., POTASSIUM CHANNELS AND OPIOID AND CANNABINOID RECEPTORS) GENES ARE STILL LIMITED. IN THIS REVIEW, WE SUMMARIZE RECENT STUDIES DETERMINING THE ROLES OF HISTONE MODIFICATIONS (INCLUDING METHYLATION, ACETYLATION, AND UBIQUITINATION), DNA METHYLATION, AND NONCODING RNAS IN NEUROPATHIC PAIN DEVELOPMENT. WE REVIEW THE EPIGENETIC WRITER, READER, AND ERASER PROTEINS THAT PARTICIPATE IN THE TRANSCRIPTIONAL CONTROL OF THE EXPRESSION OF KEY ION CHANNELS AND NEUROTRANSMITTER RECEPTORS IN THE DORSAL ROOT GANGLION AFTER TRAUMATIC NERVE INJURY, WHICH IS COMMONLY USED AS A PRECLINICAL MODEL OF NEUROPATHIC PAIN. A BETTER UNDERSTANDING OF EPIGENETIC REPROGRAMMING INVOLVED IN THE TRANSITION FROM ACUTE TO CHRONIC PAIN COULD LEAD TO THE DEVELOPMENT OF NEW TREATMENTS FOR NEUROPATHIC PAIN. 2022 13 4619 34 NERVE TRAUMA-CAUSED DOWNREGULATION OF OPIOID RECEPTORS IN PRIMARY AFFERENT NEURONS: MOLECULAR MECHANISMS AND POTENTIAL MANAGEMENTS. NEUROPATHIC PAIN IS THE MOST COMMON CLINICAL DISORDER DESTROYING THE QUALITY OF PATIENT LIFE AND LEADING TO A MARKED ECONOMIC AND SOCIAL BURDEN. OPIOIDS ARE STILL LAST OPTION FOR PHARMACOLOGICAL TREATMENT OF THIS DISORDER, BUT THEIR ANTINOCICEPTIVE EFFECTS ARE LIMITED IN PART DUE TO THE DOWNREGULATION OF OPIOID RECEPTORS IN THE PRIMARY AFFERENT NEURONS AFTER PERIPHERAL NERVE TRAUMA. HOW THIS DOWNREGULATION OCCURS IS NOT COMPLETELY UNDERSTOOD, BUT RECENT STUDIES HAVE DEMONSTRATED THAT PERIPHERAL NERVE TRAUMA DRIVES THE ALTERATIONS IN EPIGENETIC MODIFICATIONS (INCLUDING DNA METHYLATION, HISTONE METHYLATION AND MCIRORNAS), EXPRESSION OF TRANSCRIPTION FACTORS, POST-TRANSCRIPTIONAL MODIFICATIONS (E.G., RNA METHYLATION) AND PROTEIN TRANSLATION INITIATION IN THE NEURONS OF NERVE TRAUMA-RELATED DORSAL ROOT GANGLION (DRG) AND THAT THESE ALTERNATIONS MAY BE ASSOCIATED WITH NERVE TRAUMA-CAUSED DOWNREGULATION OF DRG OPIOID RECEPTORS. THIS REVIEW PRESENTS HOW OPIOID RECEPTORS ARE DOWNREGULATED IN THE DRG AFTER PERIPHERAL NERVE TRAUMA, SPECIFICALLY FOCUSING ON DISTINCT MOLECULAR MECHANISMS UNDERLYING TRANSCRIPTIONAL AND TRANSLATIONAL PROCESSES. THIS REVIEW ALSO DISCUSSES HOW THIS DOWNREGULATION CONTRIBUTES TO THE INDUCTION AND MAINTENANCE OF NEUROPATHIC PAIN. A DEEPER UNDERSTANDING OF THESE MOLECULAR MECHANISMS LIKELY PROVIDES A NOVEL AVENUE FOR PREVENTION AND/OR TREATMENT OF NEUROPATHIC PAIN. 2021 14 2407 37 EPIGENETIC RESTORATION OF VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 ALLEVIATES NERVE INJURY-INDUCED NEUROPATHIC PAIN. VOLTAGE-GATED POTASSIUM CHANNELS (KV) ARE IMPORTANT REGULATORS OF NEURONAL EXCITABILITY FOR ITS ROLE OF REGULATING RESTING MEMBRANE POTENTIAL AND REPOLARIZATION. RECENT STUDIES SHOW THAT KV CHANNELS PARTICIPATE IN NEUROPATHIC PAIN, BUT THE DETAILED UNDERLYING MECHANISMS ARE FAR FROM BEING CLEAR. IN THIS STUDY, WE USED SIRNA, MIR-137 AGOMIR, AND ANTAGOMIR TO REGULATE THE EXPRESSION OF KV1.2 IN SPINAL CORD AND DORSAL ROOT GANGLIA (DRG) OF NAIVE AND CHRONIC CONSTRICTION INJURY (CCI) RATS. KV CURRENTS AND NEURON EXCITABILITY IN DRG NEURONS WERE EXAMINED BY PATCH-CLAMP WHOLE-CELL RECORDING TO VERIFY THE CHANGE IN KV1.2 FUNCTION. THE RESULTS SHOWED THAT KV1.2 WAS DOWN-REGULATED IN DRG AND SPINAL DORSAL HORN (SDH) BY CCI. KNOCKDOWN OF KV1.2 BY INTRATHECALLY INJECTING KCNA2 SIRNA INDUCED SIGNIFICANT MECHANICAL AND THERMAL HYPERSENSITIVITY IN NAIVE RATS. CONCOMITANT WITH THE DOWN-REGULATION OF KV1.2 WAS AN INCREASE IN THE EXPRESSION OF THE MIR-137. THE TARGETING AND REGULATING OF MIR-137 ON KCNA2 WAS VERIFIED BY DUAL-LUCIFERASE REPORTER SYSTEM AND INTRATHECAL INJECTING MIR-137 AGOMIR. FURTHERMORE, RESCUING THE EXPRESSION OF KV1.2 IN CCI RATS, ACHIEVED THROUGH INHIBITING MIR-137, RESTORED THE ABNORMAL KV CURRENTS AND EXCITABILITY IN DRG NEURONS, AND ALLEVIATED MECHANICAL ALLODYNIA AND THERMAL HYPERALGESIA. THESE RESULTS INDICATE THAT THE MIR-137-MEDIATED KV1.2 IMPAIRMENT IS A CRUCIAL ETIOPATHOGENESIS FOR THE NERVE INJURY-INDUCED NEUROPATHIC PAIN AND CAN BE A NOVEL POTENTIAL THERAPEUTIC TARGET FOR NEUROPATHIC PAIN MANAGEMENT. 2021 15 4160 46 MECP2 EPIGENETIC SILENCING OF OPRM1 GENE IN PRIMARY SENSORY NEURONS UNDER NEUROPATHIC PAIN CONDITIONS. OPIOIDS ARE THE LAST OPTION FOR THE PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN, BUT THEIR ANTINOCICEPTIVE EFFECTS ARE LIMITED. DECREASED MU OPIOID RECEPTOR (MOR) EXPRESSION IN THE PERIPHERAL NERVOUS SYSTEM MAY CONTRIBUTE TO THIS. HERE, WE SHOWED THAT NERVE INJURY INDUCED HYPERMETHYLATION OF THE OPRM1 GENE PROMOTER AND AN INCREASED EXPRESSION OF METHYL-CPG BINDING PROTEIN 2 (MECP2) IN INJURED DORSAL ROOT GANGLION (DRG). THE DOWNREGULATION OF MOR IN THE DRG IS CLOSELY RELATED TO THE AUGMENTATION OF MECP2, AN EPIGENETIC REPRESSOR, WHICH COULD RECRUIT HDAC1 AND BIND TO THE METHYLATED REGIONS OF THE OPRM1 GENE PROMOTER. MECP2 KNOCKDOWN RESTORED THE EXPRESSION OF MOR IN INJURED DRG AND ENHANCED THE ANALGESIC EFFECT OF MORPHINE, WHILE THE MIMICKING OF THIS INCREASE VIA THE INTRATHECAL INFUSION OF VIRAL VECTOR-MEDIATED MECP2 WAS SUFFICIENT TO REDUCE MOR IN THE DRG. MOREOVER, HDAC1 INHIBITION WITH SUBEROYLANILIDE HYDROXAMIC ACID, AN HDAC INHIBITOR, ALSO PREVENTED MOR REDUCTION IN THE DRG OF NEUROPATHIC PAIN MICE, CONTRIBUTING TO THE AUGMENTATION OF MORPHINE ANALGESIA EFFECTS. MECHANISTICALLY, UPREGULATED MECP2 PROMOTES THE BINDING OF A HIGH LEVEL OF HDCA1 TO HYPERMETHYLATED REGIONS OF THE OPRM1 GENE PROMOTER, REDUCES THE ACETYLATION OF HISTONE H3 (ACH3) LEVELS OF THE OPRM1 GENE PROMOTER, AND ATTENUATES OPRM1 TRANSCRIPTION IN INJURED DRG. THUS, UPREGULATED MECP2 AND HDAC1 IN OPRM1 GENE PROMOTER SITES, NEGATIVELY REGULATES MOR EXPRESSION IN INJURED DRG, MITIGATING THE ANALGESIC EFFECT OF THE OPIOIDS. TARGETING MECP2/HDAC1 MAY THUS PROVIDE A NEW SOLUTION FOR IMPROVING THE THERAPEUTIC EFFECT OF OPIOIDS IN A CLINICAL SETTING. 2021 16 1630 47 DNMT3A CONTRIBUTES TO THE DEVELOPMENT AND MAINTENANCE OF BONE CANCER PAIN BY SILENCING KV1.2 EXPRESSION IN SPINAL CORD DORSAL HORN. METASTATIC BONE TUMOR-INDUCED CHANGES IN GENE TRANSCRIPTION AND TRANSLATION IN PAIN-RELATED REGIONS OF THE NERVOUS SYSTEM MAY PARTICIPATE IN THE DEVELOPMENT AND MAINTENANCE OF BONE CANCER PAIN. EPIGENETIC MODIFICATIONS INCLUDING DNA METHYLATION REGULATE GENE TRANSCRIPTION. HERE, WE REPORT THAT INTRATHECAL INJECTION OF DECITABINE, A DNA METHYLTRANSFERASE (DNMT) INHIBITOR, DOSE DEPENDENTLY ATTENUATED THE DEVELOPMENT AND MAINTENANCE OF BONE CANCER PAIN INDUCED BY INJECTING PROSTATE CANCER CELLS INTO THE TIBIA. THE LEVEL OF THE DE NOVO DNMT3A, BUT NOT DNMT3B, TIME DEPENDENTLY INCREASED IN THE IPSILATERAL L4/5 DORSAL HORN (NOT L4/5 DORSAL ROOT GANGLION) AFTER PROSTATE CANCER CELLS INJECTION. BLOCKING THIS INCREASE THROUGH MICROINJECTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS 5 (AAV5) EXPRESSING DNMT3A SHRNA INTO DORSAL HORN RESCUED PROSTATE CANCER CELLS-INDUCED DOWNREGULATION OF DORSAL HORN KV1.2 EXPRESSION AND IMPAIRED PROSTATE CANCER CELLS-INDUCED PAIN HYPERSENSITIVITY. IN TURN, MIMICKING THIS INCREASE THROUGH MICROINJECTION OF AAV5 EXPRESSING FULL-LENGTH DNMT3A INTO DORSAL HORN REDUCED DORSAL HORN KV1.2 EXPRESSION AND PRODUCED PAIN HYPERSENSITIVITY IN THE ABSENCE OF PROSTATE CANCER CELLS INJECTION. ADMINISTRATION OF NEITHER DECITABINE NOR VIRUS AFFECTED LOCOMOTOR FUNCTION AND ACUTE RESPONSES TO MECHANICAL, THERMAL, OR COLD STIMULI. GIVEN THAT DNMT3A MRNA IS CO-EXPRESSED WITH KCNA2 MRNA (ENCODING KV1.2) IN INDIVIDUAL DORSAL HORN NEURONS, OUR FINDINGS SUGGEST THAT INCREASED DORSAL HORN DNMT3A CONTRIBUTES TO BONE CANCER PAIN THROUGH SILENCING DORSAL HORN KV1.2 EXPRESSION. DNMT3A MAY REPRESENT A POTENTIAL NEW TARGET FOR CANCER PAIN MANAGEMENT. 2017 17 2214 39 EPIGENETIC MODIFICATIONS ASSOCIATED TO NEUROINFLAMMATION AND NEUROPATHIC PAIN AFTER NEURAL TRAUMA. ACCUMULATING EVIDENCE SUGGESTS THAT EPIGENETIC ALTERATIONS LIE BEHIND THE INDUCTION AND MAINTENANCE OF NEUROPATHIC PAIN. NEUROPATHIC PAIN IS USUALLY A CHRONIC CONDITION CAUSED BY A LESION, OR PATHOLOGICAL CHANGE, WITHIN THE NERVOUS SYSTEM. NEUROPATHIC PAIN APPEARS FREQUENTLY AFTER NERVE AND SPINAL CORD INJURIES OR DISEASES, PRODUCING A DEBILITATION OF THE PATIENT AND A DECREASE OF THE QUALITY OF LIFE. AT THE CELLULAR LEVEL, NEUROPATHIC PAIN IS THE RESULT OF NEURONAL PLASTICITY SHAPED BY AN INCREASE IN THE SENSITIVITY AND EXCITABILITY OF SENSORY NEURONS OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM. ONE OF THE MECHANISMS THOUGHT TO CONTRIBUTE TO HYPEREXCITABILITY AND THEREFORE TO THE ONTOGENY OF NEUROPATHIC PAIN IS THE ALTERED EXPRESSION, TRAFFICKING, AND FUNCTIONING OF RECEPTORS AND ION CHANNELS EXPRESSED BY PRIMARY SENSORY NEURONS. BESIDES, NEURONAL AND GLIAL CELLS, SUCH AS MICROGLIA AND ASTROCYTES, TOGETHER WITH BLOOD BORNE MACROPHAGES, PLAY A CRITICAL ROLE IN THE INDUCTION AND MAINTENANCE OF NEUROPATHIC PAIN BY RELEASING POWERFUL NEUROMODULATORS SUCH AS PRO-INFLAMMATORY CYTOKINES AND CHEMOKINES, WHICH ENHANCE NEURONAL EXCITABILITY. ALTERED GENE EXPRESSION OF NEURONAL RECEPTORS, ION CHANNELS, AND PRO-INFLAMMATORY CYTOKINES AND CHEMOKINES, HAVE BEEN ASSOCIATED TO EPIGENETIC ADAPTATIONS OF THE INJURED TISSUE. WITHIN THIS REVIEW, WE DISCUSS THE INVOLVEMENT OF THESE EPIGENETIC CHANGES, INCLUDING HISTONE MODIFICATIONS, DNA METHYLATION, NON-CODING RNAS, AND ALTERATION OF CHROMATIN MODIFIERS, THAT HAVE BEEN SHOWN TO TRIGGER MODIFICATION OF NOCICEPTION AFTER NEURAL LESIONS. IN PARTICULAR, THE FUNCTION ON THESE PROCESSES OF EZH2, JMJD3, MECP2, SEVERAL HISTONE DEACETYLASES (HDACS) AND HISTONE ACETYL TRANSFERASES (HATS), G9A, DNMT, REST AND DIVERSE NON-CODING RNAS, ARE DESCRIBED. DESPITE THE EFFORT ON DEVELOPING NEW THERAPIES, CURRENT TREATMENTS HAVE ONLY PRODUCED LIMITED RELIEF OF THIS PAIN IN A PORTION OF PATIENTS. THUS, THE PRESENT REVIEW AIMS TO CONTRIBUTE TO FIND NOVEL TARGETS FOR CHRONIC NEUROPATHIC PAIN TREATMENT. 2018 18 2783 33 EZH2 METHYLTRANSFERASE REGULATES NEUROINFLAMMATION AND NEUROPATHIC PAIN. RECENT STUDIES BY US AND OTHERS HAVE SHOWN THAT ENHANCER OF ZESTE HOMOLOG-2 (EZH2), A HISTONE METHYLTRANSFERASE, IN GLIAL CELLS REGULATES THE GENESIS OF NEUROPATHIC PAIN BY MODULATING THE PRODUCTION OF PROINFLAMMATORY CYTOKINES AND CHEMOKINES. IN THIS REVIEW, WE SUMMARIZE RECENT ADVANCES IN THIS RESEARCH AREA. EZH2 IS A SUBUNIT OF POLYCOMB REPRESSIVE COMPLEX 2 (PRC2), WHICH PRIMARILY SERVES AS A HISTONE METHYLTRANSFERASE TO CATALYZE METHYLATION OF HISTONE 3 ON LYSINE 27 (H3K27), ULTIMATELY RESULTING IN TRANSCRIPTIONAL REPRESSION. ANIMALS WITH NEUROPATHIC PAIN EXHIBIT INCREASED EZH2 ACTIVITY AND NEUROINFLAMMATION OF THE INJURED NERVE, SPINAL CORD, AND ANTERIOR CINGULATE CORTEX. INHIBITION OF EZH2 WITH DZNEP OR GSK-126 AMELIORATES NEUROINFLAMMATION AND NEUROPATHIC PAIN. EZH2 PROTEIN EXPRESSION INCREASES UPON ACTIVATION OF TOLL-LIKE RECEPTOR 4 AND CALCITONIN GENE-RELATED PEPTIDE RECEPTORS, DOWNREGULATION OF MIR-124-3P AND MIR-378 MICRORNAS, OR UPREGULATION OF LNCENC1 AND MALAT1 LONG NONCODING RNAS. GENES SUPPRESSED BY EZH2 INCLUDE SUPPRESSOR OF CYTOKINE SIGNALING 3 (SOCS3), NUCLEAR FACTOR (ERYTHROID-DERIVED 2)-LIKE-2 FACTOR (NRF2), MIR-29B-3P, MIR-146A-5P, AND BRAIN-SPECIFIC ANGIOGENESIS INHIBITOR 1 (BAI1). PRO-INFLAMMATORY MEDIATORS FACILITATE NEURONAL ACTIVATION ALONG PAIN-SIGNALING PATHWAYS BY SENSITIZING NOCICEPTORS IN THE PERIPHERY, AS WELL AS ENHANCING EXCITATORY SYNAPTIC ACTIVITIES AND SUPPRESSING INHIBITORY SYNAPTIC ACTIVITIES IN THE CNS. THESE STUDIES COLLECTIVELY REVEAL THAT EZH2 IS IMPLICATED IN SIGNALING PATHWAYS KNOWN TO BE KEY PLAYERS IN THE PROCESS OF NEUROINFLAMMATION AND GENESIS OF NEUROPATHIC PAIN. THEREFORE, TARGETING THE EZH2 SIGNALING PATHWAY MAY OPEN A NEW AVENUE TO MITIGATE NEUROINFLAMMATION AND NEUROPATHIC PAIN. 2023 19 5626 31 SELECTIVE REPRESSION OF GENE EXPRESSION IN NEUROPATHIC PAIN BY THE NEURON-RESTRICTIVE SILENCING FACTOR/REPRESSOR ELEMENT-1 SILENCING TRANSCRIPTION (NRSF/REST). NEUROPATHIC PAIN OFTEN DEVELOPS FOLLOWING NERVE INJURY AS A RESULT OF MALADAPTIVE CHANGES THAT OCCUR IN THE INJURED NERVE AND ALONG THE NOCICEPTIVE PATHWAYS OF THE PERIPHERAL AND CENTRAL NERVOUS SYSTEMS. MULTIPLE CELLULAR AND MOLECULAR MECHANISMS LIKELY ACCOUNT FOR THESE CHANGES; HOWEVER, THE EXACT NATURE OF THESE MECHANISMS REMAIN LARGELY UNKNOWN. A GROWING NUMBER OF STUDIES SUGGEST THAT ALTERATION IN GENE EXPRESSION IS AN IMPORTANT STEP IN THE PROGRESSION FROM ACUTE TO CHRONIC PAIN STATES AND EPIGENETIC REGULATION HAS BEEN PROPOSED TO DRIVE THIS CHANGE IN GENE EXPRESSION. IN THIS REVIEW, WE DISCUSS RECENT EVIDENCE THAT THE DNA-BINDING PROTEIN NEURON-RESTRICTIVE SILENCING FACTOR/REPRESSOR ELEMENT-1 SILENCING TRANSCRIPTION FACTOR (NRSF/REST) IS AN IMPORTANT COMPONENT IN THE DEVELOPMENT AND MAINTENANCE OF NEUROPATHIC PAIN THROUGH ITS ROLE AS A TRANSCRIPTIONAL REGULATOR FOR A SELECT SUBSET OF GENES THAT IT NORMALLY REPRESSES DURING DEVELOPMENT. 2016 20 2199 27 EPIGENETIC MODIFICATION OF DRG NEURONAL GENE EXPRESSION SUBSEQUENT TO NERVE INJURY: ETIOLOGICAL CONTRIBUTION TO COMPLEX REGIONAL PAIN SYNDROMES (PART II). CUMULATING EVIDENCE INDICATED THAT NERVE INJURY-ASSOCIATED CELLULAR AND MOLECULAR CHANGES PLAY AN ESSENTIAL ROLE IN CONTRIBUTING TO THE DEVELOPMENT OF PATHOLOGICAL PAIN, AND MORE RECENT FINDINGS IMPLICATED THE CRITICAL ROLE OF EPIGENETIC MECHANISMS IN PAIN-RELATED SENSITIZATION IN THE DRG SUBSEQUENT TO NERVE INJURY. IN THIS PART OF THE DYAD REVIEW (PART II), WE REVIEWED AND PAID SPECIAL ATTENTION ON THE ETIOLOGICAL CONTRIBUTION OF DGR GENE EXPRESSION MODULATED BY EPIGENETIC MECHANISMS OF CRPS. AS ESSENTIAL EFFECTORS TO DIFFERENT MOLECULAR ACTIVATION, WE FIRST DISCUSSED THE ACTIVATION OF VARIOUS SIGNALING PATHWAYS THAT SUBSEQUENTLY FROM NERVE INJURY, AND IN FURTHER ILLUSTRATED THE FUNDAMENTAL AND FUNCTIONAL UNDERPINNINGS OF NERVE INJURY-INDUCED PAIN, IN WHICH WE ARGUED FOR THE POTENTIAL EPIGENETIC MECHANISMS IN RESPONSE TO SENSITIZING STIMULI OR INJURY. THEREFORE, UNDERSTANDING THE SPECIFIC MEDIATING FACTORS THAT INFLUENCE INDIVIDUAL EPIGENETIC DIFFERENCES CONTRIBUTING TO PAIN SENSITIVITY AND RESPONSIVENESS TO ANALGESICS POSSESSES CRUCIAL CLINICAL IMPLICATIONS. 2014